McBane RD, Loprinzi CL, Ashrani A, et al. - Given a high rate of recurrence and death in correlation to venous thromboembolism (VTE), researchers examined whether the combined rate of major plus clinically relevant non-major bleeding in cancer patients differ in correlation to apixaban 2.5 mg vs 5 mg twice daily. Rates of venous or arterial thromboembolism were assessed as secondary efficacy outcomes. From the Academic and Community Cancer Research United consortium, they chose participating centers. It is anticipated that the trial may provide evidence supporting low-dose apixaban as a safe agent for secondary prevention of cancer-associated VTE for patients who have already completed 6-12 months of anticoagulation.